Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 7Phase 1 3

Status

Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 12OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Gynecologic 1

Conditions

Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Lung Neoplasms 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × OTHER × PM 01183 × Clear all
NCT05636111 2026-01-22

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
34 enrolled
Gynecologic

Ovarian Neoplasms

NCT05244239 2025-10-31

Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer

Emory University

Phase 1 Recruiting
22 enrolled
Thoracic

Lung Neoplasms

NCT04610658 2024-04-02

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Terminated
9 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡